First Wave BioPharma, Inc.

First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of targeted therapies for gastrointestinal diseases. The company's product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and adrulipase, a recombinant lipase enzyme designed to aid in nutrient digestion. Their pipeline includes treatments for severe acute respiratory syndrome coronavirus 2 gastrointestinal infections, ulcerative proctitis, ulcerative proctosigmoiditis, immune checkpoint inhibitor-associated colitis and diarrhea, Crohn's disease, exocrine pancreatic insufficiency in patients with cystic fibrosis, and chronic pancreatitis.

Products

• Niclosamide

• Adrulipase

• FW-COV

• FW-UP

• FW-ICI-AC

• FW-UC

• FW-CD